Publications by authors named "S T Rasmussen"
Background: Alarmins mediate type 2 T helper cell (Th2) inflammation and serve as upstream signaling elements in allergic inflammation and autoimmune responses. The alarmin interleukin (IL)-25 binds to a multi-domain receptor consisting of IL-17RA and IL-17RB subunits, resulting in the release of Th2 cytokines IL-4, IL-5, IL-9 and IL-13 to drive an inflammatory response. Therefore, the blockage of IL-17RB via SM17, a novel humanized monoclonal antibody, offers an attractive therapeutic target for Th2-mediated diseases, such as asthma.
View Article and Find Full Text PDFIntroduction: Many children expect a visit from Santa Claus, preferably on Christmas Eve and the teasing goblins are active teasing throughout the month of December. Therefore, Santa Claus and goblins must be in good shape for the activities of December. Rice pudding, Christmas pancakes, and other goodies are consumed in large quantities to help both the size of Santa Claus as well as the activity level of the Christmas teasing.
View Article and Find Full Text PDFArticle Synopsis
- * A study assessed 345 broilers using LTL tests both with and without a plastic box, finding that latencies to lie were negatively correlated with their gait scores.
- * Results indicated that LTL tests without water can effectively measure walking ability, with the box setup being more effective at distinguishing between different gait scores, while considering the effects of fatigue from the testing design.
Article Synopsis
- The study aimed to evaluate the retention rates and remission outcomes of patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who started treatment with secukinumab over 24 and 48 months.
- Data was collected from 13 European registries, revealing that retention rates were around 51%-64%, and patients with no prior biologic treatments showed better outcomes compared to those with previous treatments.
- The findings suggest that secukinumab remains effective over four years, with higher success rates in treatment-naïve patients compared to those who had already tried other therapies.